Alzheimer's disease is poised to become the world's biggest public health challenge. Today, nearly 5.4 million Americas are living with Alzheimer's disease—a number that is expected to reach 16 million by 2050. The epidemic will have dire economic consequences, bringing the annual cost of Alzheimer's in the United States from $214 billion in 2014 to $1.2 trillion by 2050, while taking an enormous emotional toll on family, friends and caregivers.
We have the power to stop this devastating disease in its tracks. By supporting scientists around the globe who are investigating novel drugs to prevent the onset of Alzheimer's, slow its progression and effectively treat its symptoms, the Alzheimer's Drug Discovery Foundation (ADDF) is working to map a new Alzheimer's future for the world.
Founded in 1998 by Leonard A. and Ronald S. Lauder, the ADDF provides critical seed funding to leading scientists conducting breakthrough drug discovery and clinical research. By accelerating promising drug candidates through the drug discovery and development pipeline and spearheading innovative public-private partnerships, we increase the chance of finding an effective treatment, and a cure, for Alzheimer’s disease.
Through the tremendous support of our donors, the ADDF has invested more than $66 million to over 450 Alzheimer’s drug discovery programs and clinical trials in academic centers and biotechnology companies in 18 countries.
Like its American affiliate, ADDF-Canda's funding is focused exclusively on translating the knowledge we have gained about the underlying causes of Alzheimer’s into drugs. To date, ADDF-Canada has funded 16 research programs in academia and biotechnology companies for a total of $3.1 million, with priority support in drug discovery and preclinical drug development, clinical trials, early detection and prevention.